查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1566968

乳癌篩檢市場：按測試類型、性別和最終用戶：2024-2033 年全球機會分析和產業預測

Breast Cancer Screening Market By Test Type , By Gender By End User : Global Opportunity Analysis and Industry Forecast, 2024-2033
出版日期: | 出版商: Allied Market Research | 英文 280 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2023年乳癌篩檢市值為29億美元，預計2024年至2033年複合年成長率為8.7%，到2033年達到67億美元。

乳癌篩檢是一項重要的公共衛生策略，旨在早期發現乳癌，這是全世界女性中最常見的癌症。這種預防措施的主要目標是在可以治療的早期階段發現癌症。乳房X光攝影是最廣泛使用的篩檢工具，經常使用已被證明可以降低乳癌死亡率。透過及早發現腫瘤，乳癌篩檢有助於增加成功治療的機會、提高存活率並減少以後更積極治療的需要。

全球乳癌篩檢市場的成長是由全球乳癌盛行率的驚人成長、人們對早期檢測方法的認知和需求的提高所推動的。根據世界衛生組織（WHO）2024年3月發布的研究，2022年全球將有約230萬名女性被診斷出罹患乳癌，通報死亡人數將達67萬人。此外，政府和醫療保健組織擴大透過宣傳宣傳活動、津貼和有組織的篩檢計劃來促進乳癌篩檢，以方便獲得篩檢服務。根據美國疾病管制與預防中心美國發布的一項研究，大約 76.4% 的 50 至 74 歲女性在過去兩年內接受過乳房 X 光檢查。這項統計數據反映了美國各地公共衛生宣傳活動的有效性和篩檢服務的可近性。此外，老年女性人口的迅速增加對市場成長做出了重大貢獻。這是因為，老年女性由於免疫力下降、基因突變累積和乳房組織變化，罹患乳癌的風險更高。越來越重視年輕女性的早期篩檢和開發非侵入性篩檢方法是進一步推動市場成長的關鍵趨勢。然而，乳癌篩檢的高成本，尤其是 3D乳房X光攝影和 MRI 等先進技術，是全球市場的主要阻礙因素。此外，由於缺乏醫療基礎設施、訓練有素的專業人員和行動篩檢單位，農村和服務欠缺地區的醫療服務有限，也嚴重限制了馬甦的市場成長。相反，數位乳房乳房X光攝影、3D乳房X光攝影和MRI等影像技術的創新正在提高乳癌篩檢的準確性和效率。這些進步使篩檢變得更加容易和可靠，並有望為全球市場擴張提供機會。為了改善偏遠和服務欠缺地區獲得乳癌篩檢的機會，正在引入移動乳房X光攝影機，以解決獲得醫療保健機會有限的問題。預計此類舉措將在不久的將來為市場成長開闢新的途徑。

全球乳癌篩檢產業按測試類型、性別、最終用戶和地區進行細分。依檢測類型分為血液標記檢測、基因檢測、影像檢查、免疫組織化學檢測等。從性別上來說，他們分為男性和女性。依最終用戶分類，可分為專科診所、醫院、診斷中心等。從區域來看，分析涵蓋北美、歐洲、亞太地區和拉丁美洲/中東/非洲。

主要發現

按檢測類型分類，2023 年影像檢查領域佔市場佔有率。

從性別來看，2023 年女性市場佔有率最大。

從最終用戶來看，醫院將成為2023年佔據佔有率的主要細分市場。

按地區分類，北美將在 2023 年佔據主導地位，而亞太地區預計在預測期內複合年成長率最高。

該報告可以客製化。

  • 監管指引
  • 根據客戶興趣加入公司簡介
  • 按國家或地區進行的附加分析 – 市場規模和預測
  • 擴大公司簡介列表
  • 歷史市場資料
  • 主要參與企業的詳細資料（Excel格式，包括位置、聯絡資訊、供應商/供應商網路等）

目錄

第1章簡介

第 2 章執行摘要

第3章 市場狀況

  • 市場定義和範圍
  • 主要發現
    • 關鍵投資機會
    • 關鍵成功策略
  • 波特五力分析
  • 市場動態
    • 促進因素
    • 抑制因素
    • 機會

第4章乳癌篩檢市場：依測試類型

  • 市場概況
  • 血液標記測試
  • 基因檢測
  • 影像檢查
  • 免疫組織化學

第5章乳癌篩檢市場：性別

  • 市場概況
  • 男性
  • 女士

第6章乳癌篩檢市場：依最終用戶分類

  • 市場概況
  • 專科診所
  • 醫院
  • 診斷中心
  • 其他

第7章乳癌篩檢市場：按地區

  • 市場概況
  • 北美洲
    • 主要市場趨勢和機遇
    • 美國乳癌篩檢市場
    • 加拿大乳癌篩檢市場
    • 墨西哥乳癌篩檢市場
  • 歐洲
    • 主要市場趨勢和機遇
    • 德國乳癌篩檢市場
    • 法國乳癌篩檢市場
    • 英國乳癌篩檢市場
    • 義大利乳癌篩檢市場
    • 西班牙乳癌篩檢市場
    • 其他歐洲乳癌篩檢市場
  • 亞太地區
    • 主要市場趨勢和機遇
    • 日本乳癌篩檢市場
    • 中國乳癌篩檢市場
    • 澳洲乳癌篩檢市場
    • 印度乳癌篩檢市場
    • 韓國乳癌篩檢市場
    • 其他亞太乳癌篩檢市場
  • 拉丁美洲/中東/非洲
    • 主要市場趨勢和機遇
    • 巴西乳癌篩檢市場
    • 沙烏地阿拉伯乳癌篩檢市場
    • 南非乳癌篩檢市場
    • 其他拉丁美洲/中東/非洲乳癌篩檢市場

第8章 競爭格局

  • 介紹
  • 關鍵成功策略
  • 10家主要企業產品圖譜
  • 競爭對手儀表板
  • 競爭熱圖
  • 主要企業定位（2023年）

第9章 公司簡介

  • Siemens Healthineers AG
  • Myriad Genetics, Inc.
  • Metabolomic Technologies Inc
  • Biocrates Lifesciences AG
  • A&G Pharmaceutical
  • Provista Diagnostics Inc
  • F. Hoffmann-La Roche AG
  • Volpara Health Limited
  • Quest Diagnostics Inc.
  • GE Healthcare
簡介目錄
Product Code: A324383

The breast cancer screening market was valued at $2.9 billion in 2023, and is projected to reach $6.7 billion by 2033, growing at a CAGR of 8.7% from 2024 to 2033.

Breast cancer screening is a critical public health strategy aimed at early detection of breast cancer, the most common cancer among women globally. The primary goal of this preventative measure is to identify cancer at an early stage when it is most treatable. Mammography is the most widely used screening tool, and its regular use has been shown to reduce mortality rates from breast cancer. By detecting tumors early, breast cancer screening increases the chances of successful treatment, improves survival rates, and can help to reduce the need for more aggressive treatments later on.

The growth of the global breast cancer screening market is driven by alarming increase in the global prevalence of breast cancer and rise in awareness and demand for early detection methods. According to a study published in March 2024 by the World Health Organization, approximately 2.3 million women were diagnosed with breast cancer and 670,000 deaths were reported globally in 2022. Furthermore, governments and healthcare organizations are increasingly promoting breast cancer screening through awareness campaigns, subsidies, and organized screening programs, which have encouraged easy access to screening services. According to a study published by the U.S. Centers for Disease Control and Prevention in 2022, approximately 76.4% of women aged 50-74 underwent a mammogram within the past two years. This statistic reflects the effectiveness of public health campaigns and the accessibility of screening services across the U.S. Moreover, surge in aged women population significantly contributes toward the market growth. This is attributed to the fact that aged women are at higher risk of developing breast cancer due to weakened immune system, accumulation of genetic mutations, and changes in breast tissue. Rise in emphasis on early screening in younger women and development of non-invasive screening methods are the key trends are that further fostering the market growth. However, high cost associated with breast cancer screening, particularly advanced technologies like 3D mammography or MRI, acts as a key deterrent factor of the global market. In addition, limited access in rural and underserved areas due to lack of healthcare infrastructure, trained professionals, and mobile screening units significantly restrains the market growth. On the contrary, innovations in imaging technologies, such as digital mammography, 3D mammography, and MRI, are enhancing the accuracy and efficiency of breast cancer screening. These advancements are making screening more accessible and reliable, which are expected to offer remunerative opportunities for the expansion of the global market during the market. To improve access to breast cancer screening in remote and underserved areas, mobile mammography units are being introduced to address the concern of limited access to healthcare. Such initiatives are anticipated to open new avenues for the market growth in the near future.

The global breast cancer screening industry is segmented into test type, gender, end user, and region. By test type, the market is divided into blood marker test, genetic test, imaging test, and immunohistochemistry test. According to gender, it is divided into male and female. As per end user, it is fragmented into specialty clinics, hospitals, diagnostic centers, and others. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

By test type, the imaging test segment dominated the market share in 2023.

According to gender, the female segment exhibited the largest market share in 2023.

As per end user, hospital emerged as the leading segment, in terms of share, in 2023.

Region wise, North America holds a dominant position in 2023; however, Asia-Pacific is expected to register highest CAGR during the forecast period.

Competition Analysis

Competitive analysis and profiles of the major players in the global breast cancer screening market include Siemens Healthineers AG, Myriad Genetics, Inc., Metabolomic Technologies Inc, Biocrates Lifesciences AG, A&G Pharmaceutical, Provista Diagnostics Inc, F. Hoffmann-La Roche AG, Volpara Health Limited, Quest Diagnostics Inc., and GE Healthcare. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to sustain the intense competition and gain a strong foothold in the global market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Test Type

  • Blood Marker Test
  • Genetic Test
  • Imaging Test
  • Immunohistochemistry Test

By Gender

  • Male
  • Female

By End User

  • Specialty Clinics
  • Hospitals
  • Diagnostic Centers
  • Other

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Siemens Healthineers AG
    • Myriad Genetics, Inc.
    • Metabolomic Technologies Inc
    • Biocrates Lifesciences AG
    • A&G Pharmaceutical
    • Provista Diagnostics Inc
    • F. Hoffmann-La Roche AG
    • Volpara Health Limited
    • Quest Diagnostics Inc.
    • GE Healthcare

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: BREAST CANCER SCREENING MARKET, BY TEST TYPE

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By Test Type
  • 4.2. Blood Marker Test
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
  • 4.3. Genetic Test
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country
  • 4.4. Imaging Test
    • 4.4.1. Key Market Trends, Growth Factors and Opportunities
    • 4.4.2. Market Size and Forecast, By Region
    • 4.4.3. Market Share Analysis, By Country
  • 4.5. Immunohistochemistry Test
    • 4.5.1. Key Market Trends, Growth Factors and Opportunities
    • 4.5.2. Market Size and Forecast, By Region
    • 4.5.3. Market Share Analysis, By Country

CHAPTER 5: BREAST CANCER SCREENING MARKET, BY GENDER

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By Gender
  • 5.2. Male
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
  • 5.3. Female
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country

CHAPTER 6: BREAST CANCER SCREENING MARKET, BY END USER

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By End User
  • 6.2. Specialty Clinics
    • 6.2.1. Key Market Trends, Growth Factors and Opportunities
    • 6.2.2. Market Size and Forecast, By Region
    • 6.2.3. Market Share Analysis, By Country
  • 6.3. Hospitals
    • 6.3.1. Key Market Trends, Growth Factors and Opportunities
    • 6.3.2. Market Size and Forecast, By Region
    • 6.3.3. Market Share Analysis, By Country
  • 6.4. Diagnostic Centers
    • 6.4.1. Key Market Trends, Growth Factors and Opportunities
    • 6.4.2. Market Size and Forecast, By Region
    • 6.4.3. Market Share Analysis, By Country
  • 6.5. Other
    • 6.5.1. Key Market Trends, Growth Factors and Opportunities
    • 6.5.2. Market Size and Forecast, By Region
    • 6.5.3. Market Share Analysis, By Country

CHAPTER 7: BREAST CANCER SCREENING MARKET, BY REGION

  • 7.1. Market Overview
    • 7.1.1 Market Size and Forecast, By Region
  • 7.2. North America
    • 7.2.1. Key Market Trends and Opportunities
    • 7.2.2. Market Size and Forecast, By Test Type
    • 7.2.3. Market Size and Forecast, By Gender
    • 7.2.4. Market Size and Forecast, By End User
    • 7.2.5. Market Size and Forecast, By Country
    • 7.2.6. U.S. Breast Cancer Screening Market
      • 7.2.6.1. Market Size and Forecast, By Test Type
      • 7.2.6.2. Market Size and Forecast, By Gender
      • 7.2.6.3. Market Size and Forecast, By End User
    • 7.2.7. Canada Breast Cancer Screening Market
      • 7.2.7.1. Market Size and Forecast, By Test Type
      • 7.2.7.2. Market Size and Forecast, By Gender
      • 7.2.7.3. Market Size and Forecast, By End User
    • 7.2.8. Mexico Breast Cancer Screening Market
      • 7.2.8.1. Market Size and Forecast, By Test Type
      • 7.2.8.2. Market Size and Forecast, By Gender
      • 7.2.8.3. Market Size and Forecast, By End User
  • 7.3. Europe
    • 7.3.1. Key Market Trends and Opportunities
    • 7.3.2. Market Size and Forecast, By Test Type
    • 7.3.3. Market Size and Forecast, By Gender
    • 7.3.4. Market Size and Forecast, By End User
    • 7.3.5. Market Size and Forecast, By Country
    • 7.3.6. Germany Breast Cancer Screening Market
      • 7.3.6.1. Market Size and Forecast, By Test Type
      • 7.3.6.2. Market Size and Forecast, By Gender
      • 7.3.6.3. Market Size and Forecast, By End User
    • 7.3.7. France Breast Cancer Screening Market
      • 7.3.7.1. Market Size and Forecast, By Test Type
      • 7.3.7.2. Market Size and Forecast, By Gender
      • 7.3.7.3. Market Size and Forecast, By End User
    • 7.3.8. UK Breast Cancer Screening Market
      • 7.3.8.1. Market Size and Forecast, By Test Type
      • 7.3.8.2. Market Size and Forecast, By Gender
      • 7.3.8.3. Market Size and Forecast, By End User
    • 7.3.9. Italy Breast Cancer Screening Market
      • 7.3.9.1. Market Size and Forecast, By Test Type
      • 7.3.9.2. Market Size and Forecast, By Gender
      • 7.3.9.3. Market Size and Forecast, By End User
    • 7.3.10. Spain Breast Cancer Screening Market
      • 7.3.10.1. Market Size and Forecast, By Test Type
      • 7.3.10.2. Market Size and Forecast, By Gender
      • 7.3.10.3. Market Size and Forecast, By End User
    • 7.3.11. Rest of Europe Breast Cancer Screening Market
      • 7.3.11.1. Market Size and Forecast, By Test Type
      • 7.3.11.2. Market Size and Forecast, By Gender
      • 7.3.11.3. Market Size and Forecast, By End User
  • 7.4. Asia-Pacific
    • 7.4.1. Key Market Trends and Opportunities
    • 7.4.2. Market Size and Forecast, By Test Type
    • 7.4.3. Market Size and Forecast, By Gender
    • 7.4.4. Market Size and Forecast, By End User
    • 7.4.5. Market Size and Forecast, By Country
    • 7.4.6. Japan Breast Cancer Screening Market
      • 7.4.6.1. Market Size and Forecast, By Test Type
      • 7.4.6.2. Market Size and Forecast, By Gender
      • 7.4.6.3. Market Size and Forecast, By End User
    • 7.4.7. China Breast Cancer Screening Market
      • 7.4.7.1. Market Size and Forecast, By Test Type
      • 7.4.7.2. Market Size and Forecast, By Gender
      • 7.4.7.3. Market Size and Forecast, By End User
    • 7.4.8. Australia Breast Cancer Screening Market
      • 7.4.8.1. Market Size and Forecast, By Test Type
      • 7.4.8.2. Market Size and Forecast, By Gender
      • 7.4.8.3. Market Size and Forecast, By End User
    • 7.4.9. India Breast Cancer Screening Market
      • 7.4.9.1. Market Size and Forecast, By Test Type
      • 7.4.9.2. Market Size and Forecast, By Gender
      • 7.4.9.3. Market Size and Forecast, By End User
    • 7.4.10. South Korea Breast Cancer Screening Market
      • 7.4.10.1. Market Size and Forecast, By Test Type
      • 7.4.10.2. Market Size and Forecast, By Gender
      • 7.4.10.3. Market Size and Forecast, By End User
    • 7.4.11. Rest of Asia-Pacific Breast Cancer Screening Market
      • 7.4.11.1. Market Size and Forecast, By Test Type
      • 7.4.11.2. Market Size and Forecast, By Gender
      • 7.4.11.3. Market Size and Forecast, By End User
  • 7.5. LAMEA
    • 7.5.1. Key Market Trends and Opportunities
    • 7.5.2. Market Size and Forecast, By Test Type
    • 7.5.3. Market Size and Forecast, By Gender
    • 7.5.4. Market Size and Forecast, By End User
    • 7.5.5. Market Size and Forecast, By Country
    • 7.5.6. Brazil Breast Cancer Screening Market
      • 7.5.6.1. Market Size and Forecast, By Test Type
      • 7.5.6.2. Market Size and Forecast, By Gender
      • 7.5.6.3. Market Size and Forecast, By End User
    • 7.5.7. Saudi Arabia Breast Cancer Screening Market
      • 7.5.7.1. Market Size and Forecast, By Test Type
      • 7.5.7.2. Market Size and Forecast, By Gender
      • 7.5.7.3. Market Size and Forecast, By End User
    • 7.5.8. South Africa Breast Cancer Screening Market
      • 7.5.8.1. Market Size and Forecast, By Test Type
      • 7.5.8.2. Market Size and Forecast, By Gender
      • 7.5.8.3. Market Size and Forecast, By End User
    • 7.5.9. Rest of LAMEA Breast Cancer Screening Market
      • 7.5.9.1. Market Size and Forecast, By Test Type
      • 7.5.9.2. Market Size and Forecast, By Gender
      • 7.5.9.3. Market Size and Forecast, By End User

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top Winning Strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top Player Positioning, 2023

CHAPTER 9: COMPANY PROFILES

  • 9.1. Siemens Healthineers AG
    • 9.1.1. Company Overview
    • 9.1.2. Key Executives
    • 9.1.3. Company Snapshot
    • 9.1.4. Operating Business Segments
    • 9.1.5. Product Portfolio
    • 9.1.6. Business Performance
    • 9.1.7. Key Strategic Moves and Developments
  • 9.2. Myriad Genetics, Inc.
    • 9.2.1. Company Overview
    • 9.2.2. Key Executives
    • 9.2.3. Company Snapshot
    • 9.2.4. Operating Business Segments
    • 9.2.5. Product Portfolio
    • 9.2.6. Business Performance
    • 9.2.7. Key Strategic Moves and Developments
  • 9.3. Metabolomic Technologies Inc
    • 9.3.1. Company Overview
    • 9.3.2. Key Executives
    • 9.3.3. Company Snapshot
    • 9.3.4. Operating Business Segments
    • 9.3.5. Product Portfolio
    • 9.3.6. Business Performance
    • 9.3.7. Key Strategic Moves and Developments
  • 9.4. Biocrates Lifesciences AG
    • 9.4.1. Company Overview
    • 9.4.2. Key Executives
    • 9.4.3. Company Snapshot
    • 9.4.4. Operating Business Segments
    • 9.4.5. Product Portfolio
    • 9.4.6. Business Performance
    • 9.4.7. Key Strategic Moves and Developments
  • 9.5. A&G Pharmaceutical
    • 9.5.1. Company Overview
    • 9.5.2. Key Executives
    • 9.5.3. Company Snapshot
    • 9.5.4. Operating Business Segments
    • 9.5.5. Product Portfolio
    • 9.5.6. Business Performance
    • 9.5.7. Key Strategic Moves and Developments
  • 9.6. Provista Diagnostics Inc
    • 9.6.1. Company Overview
    • 9.6.2. Key Executives
    • 9.6.3. Company Snapshot
    • 9.6.4. Operating Business Segments
    • 9.6.5. Product Portfolio
    • 9.6.6. Business Performance
    • 9.6.7. Key Strategic Moves and Developments
  • 9.7. F. Hoffmann-La Roche AG
    • 9.7.1. Company Overview
    • 9.7.2. Key Executives
    • 9.7.3. Company Snapshot
    • 9.7.4. Operating Business Segments
    • 9.7.5. Product Portfolio
    • 9.7.6. Business Performance
    • 9.7.7. Key Strategic Moves and Developments
  • 9.8. Volpara Health Limited
    • 9.8.1. Company Overview
    • 9.8.2. Key Executives
    • 9.8.3. Company Snapshot
    • 9.8.4. Operating Business Segments
    • 9.8.5. Product Portfolio
    • 9.8.6. Business Performance
    • 9.8.7. Key Strategic Moves and Developments
  • 9.9. Quest Diagnostics Inc.
    • 9.9.1. Company Overview
    • 9.9.2. Key Executives
    • 9.9.3. Company Snapshot
    • 9.9.4. Operating Business Segments
    • 9.9.5. Product Portfolio
    • 9.9.6. Business Performance
    • 9.9.7. Key Strategic Moves and Developments
  • 9.10. GE Healthcare
    • 9.10.1. Company Overview
    • 9.10.2. Key Executives
    • 9.10.3. Company Snapshot
    • 9.10.4. Operating Business Segments
    • 9.10.5. Product Portfolio
    • 9.10.6. Business Performance
    • 9.10.7. Key Strategic Moves and Developments